The interpretation of Variants of Uncertain Significance remains a significant hurdle in modern genomic medicine. Although laboratories classify these results as inconclusive, clinical practice often tells a different story. A recent systematic review explores the depth of this issue across diverse healthcare settings. Specifically, researchers examined how these ambiguous results steer the course of patient management and whether clinicians adhere to standard guidelines. Many practitioners find themselves in a difficult position when faced with such uncertainty, as the pressure to provide definitive care often outweighs the available genetic evidence.

Clinical Management of Variants of Uncertain Significance

The study analyzed 45 distinct articles to determine the frequency of clinical intervention based on uncertain results. Interestingly, 67% of the reviewed studies reported that Variants of Uncertain Significance directly influenced care decisions. Consequently, clinicians often move beyond the recommended \"wait and see\" approach. The review identified three primary descriptive patterns in how physicians handle these findings. Some professionals treat them as benign, while others view them as weak positives or even fully pathogenic. This variability suggests that the clinical application of genetic data is far from standardized.

Furthermore, the data suggests that certain contexts increase the likelihood of active intervention. For instance, clinicians working outside the field of oncology are more likely to act on these findings compared to their oncology counterparts. Additionally, prospective studies and screening-based decisions showed a higher rate of clinical impact. These findings highlight a critical gap between laboratory classifications and real-world medical practice. Therefore, the medical community must address these inconsistencies to prevent potential over-treatment or patient anxiety.

Addressing the Gap in Genomic Medicine

Because these variants appear so frequently in large genetic panels, standardizing the response is essential for patient safety. Clinicians must balance the risk of unnecessary procedures against the potential for missing actionable risks. Currently, many decisions remain clinician-centered rather than patient-centered. Consequently, the review calls for more robust, evidence-based frameworks to guide these complex interactions. Furthermore, improving genetic literacy among non-geneticists could reduce the tendency to treat uncertain results as definitive pathogenic findings. Ultimately, the goal is to ensure that genomic testing provides clarity rather than additional confusion.

Frequently Asked Questions

How do Variants of Uncertain Significance affect treatment?

Research indicates that in 67% of reported cases, these variants lead to changes in clinical care, such as increased screening or surgical interventions, despite their inconclusive classification.

Are these variants more likely to be treated as pathogenic?

Yes, the systematic review found that some clinicians treat these variants as \"weak positives\" or pathogenic, especially in screening settings or medical fields outside of oncology.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ayappa S et al. How Variants of Uncertain Significance Impact Clinical Decisions: A Systematic Review. Genet Med. 2026 May 12. doi: undefined. PMID: 42117370.

Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.

Federici G, Soddu S. Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from BRCA1 and BRCA2 mutations. J Exp Clin Cancer Res. 2020;39(1):46.